Our study clearly defines this uniqueness of the NAFLD marker, the AST-to-ALT ratio, as a prerequisite for diagnosing metabolic syndrome, but further verification is needed from long-term epidemiological studies. The gene discussed is GPT; the disease is metabolic syndrome.